1. Home
  2. APLT vs HGBL Comparison

APLT vs HGBL Comparison

Compare APLT & HGBL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • APLT
  • HGBL
  • Stock Information
  • Founded
  • APLT 2016
  • HGBL 1937
  • Country
  • APLT United States
  • HGBL United States
  • Employees
  • APLT N/A
  • HGBL N/A
  • Industry
  • APLT Biotechnology: Pharmaceutical Preparations
  • HGBL Business Services
  • Sector
  • APLT Health Care
  • HGBL Consumer Discretionary
  • Exchange
  • APLT Nasdaq
  • HGBL Nasdaq
  • Market Cap
  • APLT 63.6M
  • HGBL 66.7M
  • IPO Year
  • APLT 2019
  • HGBL N/A
  • Fundamental
  • Price
  • APLT $0.42
  • HGBL $1.89
  • Analyst Decision
  • APLT Buy
  • HGBL Strong Buy
  • Analyst Count
  • APLT 6
  • HGBL 1
  • Target Price
  • APLT $6.10
  • HGBL $4.00
  • AVG Volume (30 Days)
  • APLT 883.6K
  • HGBL 43.3K
  • Earning Date
  • APLT 11-06-2025
  • HGBL 11-06-2025
  • Dividend Yield
  • APLT N/A
  • HGBL N/A
  • EPS Growth
  • APLT N/A
  • HGBL N/A
  • EPS
  • APLT N/A
  • HGBL 0.10
  • Revenue
  • APLT $121,000.00
  • HGBL $48,940,000.00
  • Revenue This Year
  • APLT N/A
  • HGBL $23.07
  • Revenue Next Year
  • APLT $5,931.24
  • HGBL $4.49
  • P/E Ratio
  • APLT N/A
  • HGBL $18.97
  • Revenue Growth
  • APLT N/A
  • HGBL N/A
  • 52 Week Low
  • APLT $0.30
  • HGBL $1.52
  • 52 Week High
  • APLT $10.62
  • HGBL $2.39
  • Technical
  • Relative Strength Index (RSI)
  • APLT 38.92
  • HGBL 42.72
  • Support Level
  • APLT $0.43
  • HGBL $1.87
  • Resistance Level
  • APLT $0.46
  • HGBL $1.92
  • Average True Range (ATR)
  • APLT 0.03
  • HGBL 0.06
  • MACD
  • APLT -0.01
  • HGBL 0.00
  • Stochastic Oscillator
  • APLT 0.35
  • HGBL 30.77

About APLT Applied Therapeutics Inc.

Applied Therapeutics Inc is a clinical-stage biopharmaceutical company, developing a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need. The company's drug compounds pipeline includes AT-007 which is a novel central nervous system, penetrant ARI that it is developing for the treatment of rare metabolic diseases, including Galactosemia and Sorbitol Dehydrogenase (SORD) Deficiency, AT-001 for the treatment of diabetic cardiomyopathy, and AT-003 for the treatment of diabetic retinopathy.

About HGBL Heritage Global Inc.

Heritage Global Inc values and monetizes industrial and financial assets by providing acquisition, disposition, valuation, and lending services for surplus and distressed assets. It aids in facilitating the economy by diverting useful industrial assets from landfills and operating a supply chain by overseeing the post-sale account activity of financial assets. The group operates in four segments namely Auction and Liquidation; Refurbishment and Resale; Brokerage and Specialty Lending. It generates maximum revenue from the Auction and Liquidation segment. The Auction and Liquidation segment, through HGP, operates as a full-service auction, appraisal, and asset advisory firm, including the acquisition of turnkey manufacturing facilities and used industrial machinery and equipment.

Share on Social Networks: